Login
Registrieren
Passwort zurücksetzen
Veröffentlichen & Verteilen
Verlagslösungen
Vertriebslösungen
Themen
Allgemein
Altertumswissenschaften
Architektur und Design
Bibliotheks- und Informationswissenschaft, Buchwissenschaft
Biologie
Chemie
Geowissenschaften
Geschichte
Industrielle Chemie
Informatik
Jüdische Studien
Kulturwissenschaften
Kunst
Linguistik und Semiotik
Literaturwissenschaft
Materialwissenschaft
Mathematik
Medizin
Musik
Pharmazie
Philosophie
Physik
Rechtswissenschaften
Sozialwissenschaften
Sport und Freizeit
Technik
Theologie und Religion
Wirtschaftswissenschaften
Veröffentlichungen
Zeitschriften
Bücher
Konferenzberichte
Verlage
Blog
Kontakt
Suche
EUR
USD
GBP
Deutsch
English
Deutsch
Polski
Español
Français
Italiano
Warenkorb
Home
Zeitschriften
Asian Biomedicine
Band 15 (2021): Heft 4 (August 2021)
Uneingeschränkter Zugang
Potential of amentoflavone with antiviral properties in COVID-19 treatment
Akhilesh Vikram Singh
Akhilesh Vikram Singh
| 20. Aug. 2021
Asian Biomedicine
Band 15 (2021): Heft 4 (August 2021)
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zusammenfassung
Artikel
Figuren und Tabellen
Referenzen
Autoren
Artikel in dieser Ausgabe
Vorschau
PDF
Zitieren
Teilen
Article Category:
Mini review
Online veröffentlicht:
20. Aug. 2021
Seitenbereich:
153 - 159
DOI:
https://doi.org/10.2478/abm-2021-0020
Schlüsselwörter
amentoflavone
,
COVID-19
,
CYP450 inhibitor
,
flavonoid
,
SARS-CoV
© 2021 Akhilesh Vikram Singh, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
Molecular docking showing the binding of amentoflavone to the receptor binding domain of spike glycoprotein of SARS-CoV-2 (Research Collaboratory for Structural Bioinformatics Protein (RCSB) Data Base ID 6M17, chain E). Residues of the receptor binding domain interacting with amentoflavone are shown in yellow. Adapted from Miroshnychenko KV, Shestopalova A. Combined use of amentoflavone and ledipasvir could interfere with binding of spike glycoprotein of SARS-CoV-2 to ACE2: the results of molecular docking study. ChemRxiv. Preprint. doi: 10.26434/chemrxiv.12377870.v1, with kind permission of the authors. ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2
Interaction of amentoflavone with the inflammatory network and CYPs. Network drawn using STITCH showing chemical–protein interactions based on literature. In the network, nodes are proteins or chemicals and the edges represent the functional associations. The grey edges represent confidence with the line thickness indicating the strength of data support. Adapted from http://stitch.embl.de [25]. Inset shows the binding of amentoflavone to SARS-CoV 3CLpro. Adapted minimally and reprinted from [17] Bioorganic and Medicinal Chemistry, 18, Young Bae Ryu, Hyung Jae Jeong, Jang Hoon Kim, Young Min Kim, Ji-Young Park, Doman Kim, Thi Thanh Hanh Naguyen, Su-Jin Park, Jong Sun Chang, Ki Hun Park, Mun-Chual Rho, Woo Song Lee, Biflavonoids from Torreya nucifera displaying SARS-Co V 3CLpro inhibition, page 7944, Copyright (2010), with permission from Elsevier. The network shows the association of amentoflavone with CYPs and the inflammatory pathway to support the hypothesis for using amentoflavone as an adjunct therapy for COVID-19. 3CLpro, 3-chymotrypsin-like protease; COVID-19, Coronavirus disease-2019; CYP, cytochrome P450; ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; GRB2, growth factor receptor-bound protein 2; HSP90AA1, heat shock protein 90α family class A member 1; IL1B, interleukin 1β; IL6, interleukin 6; IL6R, interleukin 6 receptor; IL6ST, interleukin 6 signal transducer; OPRD1, opioid receptor δ1; OPRM1, opioid receptor μ1; PPARG, peroxisome proliferator-activated receptor γ; SARS-CoV, severe acute respiratory syndrome coronavirus; TNF, tumor necrosis factor α.
Vorschau